Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?

Nephrol Dial Transplant. 2007 Jan;22(1):32-6. doi: 10.1093/ndt/gfl573. Epub 2006 Oct 20.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Antineutrophil Cytoplasmic / metabolism*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody Formation
  • B-Lymphocytes / metabolism
  • Clinical Trials as Topic
  • Cytoplasm / metabolism*
  • Granulomatosis with Polyangiitis / drug therapy
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Models, Biological
  • Neutrophils / immunology*
  • Rituximab
  • Vasculitis / drug therapy*

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab